The UMBRELLA Strategy continued its portfolio rotation towards Artificial Intelligence and advanced technologies this week.
SpaceX became the largest position after further purchases, while Palantir Technologies was significantly increased. Dell Technologies was added as a new stock, further strengthening the focus on AI infrastructure.
At the same time, Bayer was completely sold off, while positions in Revolution Medicines and Johnson & Johnson were reduced. These adjustments reflect a stronger concentration on technology alongside selective engagement in the healthcare sector.
The portfolio currently comprises nine positions with an equity ratio of 97.4% and a liquidity ratio of 2.6%.
SpaceX: New Largest Position and RED HOT CHILI MUMAK of the Week
SpaceX has risen to become the largest position within the UMBRELLA Strategy.
Its weighting increased from approximately 13.4% to 18.4%, surpassing SpaceX‘s previous largest position, Revolution Medicines.
Operational developments also remained in focus. SpaceX continued preparations for Starship launches from Florida.
With a performance of approximately +16.7% since its inclusion, SpaceX was named this week’s RED HOT CHILI MUMAK. This award underscores the company’s growing importance within the strategy.
Palantir Technologies: Position Significantly Increased
The position in Palantir Technologies was significantly expanded. The portfolio weighting increased from approximately 13.3% last week to currently 17.9%.
With a performance of approximately +12.3% since its inclusion, Palantir is now the second-largest position in the strategy.
Dell Technologies: New Addition to the UMBRELLA Strategy
A new stock, Dell Technologies, was added to the UMBRELLA Strategy. The position currently has a weighting of approximately 3.2%.
Dell complements the existing semiconductor positions in Micron Technology and Intel, expanding the strategy’s engagement in various areas of the AI infrastructure market.
Revolution Medicines: Position Reduced After Price Weakness
Revolution Medicines again came under selling pressure during the week, accompanied by broader weakness in the biotechnology sector.
On October 6, biotechnology stocks experienced significant price losses, which also affected Revolution Medicines. The decline reflected a generally subdued market sentiment in the biotechnology sector, without a clearly identifiable new company-specific setback.
In the wake of the price weakness, the position in Revolution Medicines within the UMBRELLA Strategy was reduced.
Despite the adjustment, Revolution Medicines remains an important position in the healthcare sector.
Bayer: Complete Exit from the Strategy
Bayer was completely sold off from the UMBRELLA Strategy.
Following sustained price weakness, the remaining position was closed at prices between approximately EUR 43.00 and EUR 44.15. The reported losses ranged between approximately -2.6% and -5.1%.
This exit concludes the recent series of position reductions in Bayer. At the same time, capital is freed up for the strategy’s stronger technology focus.
Micron and Intel: Volatility in the Semiconductor Sector
The semiconductor sector again experienced increased volatility. Concerns about the pace of AI-related investments weighed on technology stocks.
Micron Technology and Intel were also affected by the broader price declines in the semiconductor sector. However, long-term interest in AI infrastructure and demand from data centers remained.
Both companies remain significant positions within the UMBRELLA Strategy, with current weightings of approximately 12.0% for Micron and 10.7% for Intel.
Johnson & Johnson: Weighting in Healthcare Sector Reduced
The position in Johnson & Johnson was partially reduced. The weighting decreased from approximately 9.0% last week to currently 6.2%.
Eli Lilly remains part of the strategy with a weighting of 9.3%, continuing to ensure selective engagement in the healthcare sector.
Current Positioning of the UMBRELLA Strategy
| Position | Weighting | Performance since inclusion |
|---|---|---|
| SpaceX | 18.3% | +16.4% |
| Palantir Technologies | 17.9% | +12.6% |
| Revolution Medicines | 15.4% | +19.6% |
| Micron Technology | 12.0% | +1.8% |
| Intel | 10.7% | −6.8% |
| Eli Lilly | 9.3% | +8.8% |
| Johnson & Johnson | 6.2% | +7.2% |
| Alphabet | 4,3 % | +2,3 % |
| Dell Technologies | 3.2% | +0.7% |
Equity ratio: 97.4%
Liquidity: 2.6%
Source: wikifolio.com, UMBRELLA Strategy, Portfolio status as of October 9, 2026.
Inside UMBRELLA Podcast
Do you want to know more about the UMBRELLA Strategy?
Then listen to the “Inside UMBRELLA” podcast:
Conclusion
The past week marked another important step in the technology-oriented reorientation of the UMBRELLA Strategy.
SpaceX and Palantir now account for more than 36% of the portfolio, while the new addition of Dell Technologies further expands the commitment to AI infrastructure.
At the same time, the complete exit from Bayer and the reductions in Revolution Medicines and Johnson & Johnson illustrate the ongoing adaptation of the portfolio to market developments.
With nine positions and an equity ratio of 97.4%, the strategy remains focused on Artificial Intelligence, semiconductors, advanced technologies, and selected companies from the healthcare sector.
